INTRODUCTION

Menorrhagia, although is not life threatening, but it has a major impact on personal, family and social life of a woman, effecting her household work and workplace responsibilities. It is defined as menstruation periods at regular cycles but with excessive flow which may last for more than seven days. Menorrhagia can cause menstrual bleeding of more than 80 mL in each cycle.1,2

In treating menorrhagia the primary aim should be to improve quality of life of woman. WHO defines Quality of Life as individuals’ perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns. It is a complex phenomenon.3 One in five women end up in hysterectomy by the age of 60 years1 and most of them have no detectable pelvic pathology. The high cost associated with medical management, means that menorrhagia places a huge financial burden on the family.3
The overall aim of management of menorrhagia is to reduce the adverse impact of the condition thereby improving the sufferer’s ‘quality of life’ (QoL). Management of menorrhagia depends upon the threshold of patient and her expectations about her symptoms. Exact amount of blood loss is almost difficult to measure. Assessment of menstrual flow is highly subjective and gauging the severity of the condition by objective assessment of menstrual blood loss is impractical, the use of QoL instruments in menorrhagia research is increasing to allow more objective assessment of clinical outcomes of therapeutic interventions. The objective of this study was to determine effect of menorrhagia on quality of life of a woman.

METHODS

A case control study was designed, 360 women who presented in Outpatient Gynaecology & Obstetrics Department of AMTH (Arif Memorial Teaching Hospital Lahore) from January 2017 to December 2017 (1 year) were included in study through purposive sampling. Sample size was calculated using open epi tool. Those patients who had menorrhagia were included in group A (cases; n=160). Group B comprises of Age group matched controls. The participants were interviewed by using a questionnaire and SF 36 questionnaire of quality of life. The questionnaire was prepared by author through literature review, the questions were based on history, symptoms and severity of diseases. The severity of menstrual symptoms and sign were determined from answers to questions about duration of periods, number of pads and additional clothes, tampons used, experience of flooding and passing clots, frequency of blood staining of clothes and extent of dysmenorrhea.

The San Francisco-36 Health Survey is a multi-purpose, short-form health survey which contains 36 questions. It yields an eight-scale profile of scores as well as summary physical and mental measures. It measures health-related quality of life on eight dimensions which include physical functioning, social functioning, role limitations due to physical problems, role limitations due to emotional problems, general mental health, energy and vitality, bodily pain and general health perceptions. This is a broad instrument and it has been validated for menorrhagia in a study by Sculpher MJ et al., but it has certain limitations, that are discussed later. We obtained ethical approval from ethical review board of the institution. Participants were asked to give consent. Data was entered into SPSS 21 and results were obtained as frequency, mean and p values. Mean and percentage were calculated for SF36 questionnaire and response to questions was presented in the form of frequency and percentage. Independent sample T test was used to determine the statistically significant difference. P-value of 0.05 or less was considered as significant.

Table I: Comparison of quality of life in female with or without menorrhagia controlling for age.

| Age Group | Menorrhagia | Mean | Std. Deviation | p-value |
|-----------|-------------|------|----------------|---------|
| <20       | Yes         | 17.14| 1.57           | <0.001* |
|           | No          | 6.50 | 2.78           |         |
| 21-25     | Yes         | 13.38| 3.88           | <0.001* |
|           | No          | 4.00 | 2.07           |         |
| 26-30     | Yes         | 15.13| 3.38           | <0.001* |
|           | No          | 4.49 | 2.55           |         |
| 31-35     | Yes         | 15.18| 2.78           | <0.001* |
|           | No          | 5.17 | 3.49           |         |
| 36-40     | Yes         | 16.37| 2.54           | <0.001* |
|           | No          | 10.50| 0.58           |         |
| >40       | Yes         | 16.73| 2.57           | <0.001* |
|           | No          | 3.00 | 0.00           |         |

*Independent sample t test, P-value significant at 0.001.
RESULTS

In this study 230 females were included. The mean age of the participants was 35.56±8.85 years. Regarding duration of menorrhagia; 11% of the patients had menorrhagia for more than four years, 22% had menorrhagia for 1-2 years and 1.2% for three months. Responding to the question about duration of bleeding during each cycle; 16% had bleeding for three days, 70% had bleeding for 4-8 days and 11.9% had bleeding for more than 8-12 days. Among those who had menorrhagia, 33.0% used 2-3 pads per day, 47.2% 4-6 pads/day, 15.1% 6-8 pads/day, 4.1% 8-10 pads per day and 6% used more than 10 pads per day; thus contributing to huge financial burden on the family.

We compared quality of life in both case and control groups and the results showed that among all age groups the quality of life was better in female without menorrhagia as compared to those with menorrhagia (p-value <0.001).

DISCUSSION

This study was conducted to determine the magnitude of menorrhagia on the quality of life of a woman. Review of different studies shows that although menorrhagia is non-life threatening, condition, but it has a tremendous effect on quality of life of female. It also has a negative effect on their family life.6 WHO defines health as “A state of complete physical, mental, and social well-being not merely the absence of disease” (measuring quality of life). In recent days the perception of health has been broadened and now it includes social, psychological and physical aspect of a life.7 The other development is shifting of quality of life from physician’s perception to the individual’s subjective feeling of wellbeing.8 SF 36 is a generic instrument and used in this study to see all above described aspects on QOL of a patient suffering from menorrhagia. But the analysis of the disease related effects has been limited by available tools for measuring outcome of the disease process and effect on quality of life. That is why it is necessary to develop health related quality of life instruments regarding menorrhagia or any other abnormal bleeding, so objective assessment of quality of life can be carried out. This study is an attempt to see the impact of menorrhagia on quality of life of a woman.

High cost related to treatment of menorrhagia, adds a huge financial burden on the family, the estimated annual direct and indirect financial burden is actually under estimated. In a systemic review conducted by DeaN BB et al the annual cost of treatment of menorrhagia/abnormal uterine bleeding in USA was $1 billion The result found in my study disclosed that cost in terms of rise in number of pads used for protection was bigger in case group. Still future studies are required to estimate annual cost on treatment and management of menorrhagia particularly in Pakistan.9 In poor countries like Pakistan where day to day needs of a family are meet with great struggle, women usually ignore such problems as emphasized by Hussain et al.10 The social taboo associated with speaking about periods force women to stay silent thus resulting in medical problems, like anemia, and psychological stress. These facts hamper the physical and mental well-being of a woman, who actually act as a backbone of her family thus effecting HEALTH of whole family.

Clinical findings that are most strongly related with blood loss volume are the rate of changing sanitary protection during full flow, the total number of pads used, iron status of a woman, the size of clots and need to change protection during social gatherings or during nights. In routine clinical practice we usually depend on on these subjective findings based on perception of a woman, but there is no reliable tool that can assess blood loss accurately. It is apparent that all these symptoms and sign were increased in case group. In our study women describe severe symptoms after menorrhagia hence they used more than one product together for protection, they experience
soaking of their clothes and bed sheets. Likewise, they experience more pain. These findings were comparable to the findings discussed by Gokyildiz S et al. and Warner PE et al. There are many possible cause of menorrhagia like fibroids, endometriosis, adenomyosis, bleeding disorders, endometrial hyperplasia, and many more, but objective of treatment of all causes is twofold, first is to reduce or stop menorrhagia and second is to improve quality of life.

In our study the quality of life was better among all age groups in control group (without menorrhagia) as compared to case group (with menorrhagia) p-value <0.001. Alike findings were observed in literature that menorrhagia disturb quality of life in an undesirable way. According to one more study by Kadir RA et al the health-related quality measured by SF36 was below 25th percentile for the US general female population suffering from menorrhagia.

Limitations of the study: A validated Urdu version of SF36 questionnaire was lacking. Sf 36 is inappropriate to be used because outcome of measure taken in treatment of menorrhagia are not addressed. So, it is recommended that specific disease related tool that measure quality of life in patients can be used for future study purpose. Further future research should be focused on qualitative aspect of this study so as to have in depth understanding about patient’s perception and experience with menorrhagia. It will be better for effective ness of treatment and care given to the patients.

REFERENCES
1. Gokyildiz S, Aslan E, Beji NK, Medci M. The Effects of Menorrhagia on Women’s Quality of Life: A case-control study. ISRN Obstet Gynecol. 2013;2013:918179. doi: 10.1155/2013/918179
2. Apgar BS, Kaufman AH, George-Nwogu U, Kittendorf A. Treatment of menorrhagia. Am Fam Physician. 2007;75(12):1813-1819.
3. WHO. WHOQOL: Measuring quality of life. Psychol Med. 1998;28(3):551-558. Available from: http://www.who.int/mental_health/media/68.pdf
4. Ware JE, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998;51(11):903-912
5. Sculpher MJ, Dwyer N, Byford S, Stirrat GM. Randomised trial comparing hysterectomy and transcervical endometrial resection: Effect on health related quality of life ans costs two years after surgery. Br J Obstet Gynaecol. 1996;103(2):142-9.
6. Shankar M, Chi C, Kadir RA. Review of quality of life: Menorrhagia in women with or without inherited bleeding disorders. Haemophilia. 2008;14(1):15-20. doi: 10.1111/j.1365-2516.2007.01586.x
7. Meeberg GA. Quality of life: a concept analysis. J Adv Nurs. 1993;18(1):32-38.
8. Bowling A. Reviews Measuring Health: a review of quality of life measurement scales (Second Edition ). Appl Occup Psychol Employ Disabil. 1999;2(1):59-62.
9. Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in Abnormal Uterine Bleeding. Curr Med Res Opin [Internet]. 2004;20(2):139-54. Available from: http://www.tandfonline.com/doi/full/10.1185/030079903125002801
10. Hussain S, Maiz B, Aqeel S, Zaidi N. Issues in reproductive health in females having inherited bleeding disorders in Pakistan. Haemophilia. 2017;23:e367-e370. doi: 10.1111/hae.13254
11. Bruinvels G, Burden RJ, Cushway T, Brown N, Pedlar C, Richards T. THE IMPACT OF HEAVY MENSTRUAL BLEEDING (MENORRHAGIA) AND IRON STATUS IN EXERCISING FEMALES. Br J Sports Med [Internet]. 2017 Feb 1;51(4):304 LP-304. Available from: http://bjsm.bmj.com/content/51/4/304.1
12. Warner PE, Critchley HOD, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia I: Measured blood loss, clinical features, and outcome in women with heavy periods - A survey with follow-up data. Am J Obstet Gynecol. 2004;190(5):1216-23
13. Neelakantan D, Omojole F, Clark TJ, Gupta JK, Khan KS. Quality of life instruments in studies of chronic pelvic pain: A systematic review. J Obstet Gynaecol. 2004;24(8):851-858.
14. Bruinvels G, Burden R, Brown N, Richards T, Pedlar C. The prevalence and impact of heavy menstrual bleeding (Menorrhagia) in elite and non-elite athletes. PLoS One. 2016;11(2):1-8.
15. Kadir RA, Edlund M, Von Mackensen S. The impact of menstrual disorders on quality of life in women with inherited bleeding disorders. Haemophilia. 2010;16(5):832-839.